BioView: How Much Flexibility Is Really Left After Adjustment Shares, Leases, and Bank Credit
BioView ended 2025 with NIS 4.92 million of cash, but the clean buffer is smaller than the headline suggests: NIS 1.036 million was already booked as an adjustment-share liability, leases consumed NIS 1.906 million of cash in 2025, and the post-balance-sheet credit that actually arrived was a secured NIS 1 million On-Call bank loan.
The main article already established that BioView's bottleneck is not just growth, but funding the path forward. This follow-up strips the question down further: after adjustment shares, lease cash uses, and the quality of the credit added after the balance sheet date, how much real room is left.
This is an all-in cash-flexibility question, not a normalized cash-generation question. The issue is not how much the business might produce in a cleaner scenario, but how much room is left after the cash uses that already happened, after dilution layers that are already sitting on the balance sheet, and after testing which financing sources actually turned into cash. That matters here because early 2026 generated several financing headlines around BioView, but only part of that story became real liquidity.
Positive Working Capital Is Not a Cash Buffer
The bigger number is the misleading one. At the end of 2025 the company reported positive working capital of NIS 7.553 million. On the surface that sounds reasonably comfortable. But there is a large gap between real liquidity and assets that take time to convert or depend on execution: cash and cash equivalents were only NIS 4.92 million, while inventory alone stood at NIS 6.074 million. Trade receivables were another NIS 1.812 million, so not everything inside working capital carries the same liquidity quality.
There is another layer that can easily be missed. The working-capital figure already includes part of the problem. Inside current liabilities of NIS 8.6 million sits a fair-value financial liability of NIS 1.036 million. That is not a normal loan and it is not a trade payable. It is the accounting recognition of the adjustment-share mechanism, meaning the possibility that the company will have to pay later through additional dilution because the share price fell below the reference price of the 2025 placements.
Cash flow makes the same point from another angle. Operating cash flow was negative NIS 3.057 million in 2025. Financing cash flow was positive by only NIS 425 thousand, even though the company raised NIS 2.129 million net from share issuances, because it also paid NIS 1.704 million in lease principal during the year. The result was a decline in cash from NIS 8.22 million to NIS 4.92 million. Even after equity came in, the cushion still shrank.
That chart is the right way to read year-end 2025. The company does have positive working capital, but a large part of it sits in inventory rather than cash. At the same time, current liabilities already include the NIS 1.036 million adjustment-share liability. So the NIS 7.553 million headline cannot be treated as freely available liquidity.
Adjustment Shares Have Already Moved Onto the Balance Sheet
The potential dilution from 2025 is no longer a footnote. It has already moved onto the balance sheet. In April, June, and July 2025 the company completed three private placements at NIS 0.30 per share: 7,166,666 shares in April, 1,000,000 shares in June, and 1,333,333 shares in July. All three carried the same mechanism: if the average share price over the ten trading days before the 12-month test date is below NIS 0.30, the company must issue additional adjustment shares under the terms of the agreements.
That matters for two reasons. First, because the company had already recognized the related liability at year-end: NIS 782 thousand for the April tranche, NIS 109 thousand for the June tranche, and NIS 145 thousand for the July tranche, together NIS 1.036 million. Second, because those test dates fall directly into 2026, the same year in which the company is also leaning on cost cuts and short-term bank credit.
There is another detail that sharpens the quality of the proceeds the company actually received. In the April placement, which had gross proceeds of NIS 2.15 million and net proceeds of NIS 1.838 million, the company stated that by year-end it had collected only NIS 1.75 million, with the remaining consideration expected in April 2026. In other words, even within the 2025 equity proceeds, not all of the headline amount was already sitting in cash at the end of the year.
The valuation of this liability was based on 46% expected volatility, a 3.9% risk-free rate, and an expected term of roughly half a year. That is a useful signal in itself. The company is not treating the mechanism as a remote technicality. It has already priced it as a fair-value liability. Put differently, the share is not just a future financing currency. It is already a financing currency that carries a built-in claim.
As of April 6, 2026 the share price was 16.5 agorot. That does not by itself determine the final adjustment-share count, because the agreements use the ten-day average before each anniversary date. But it does set the starting point clearly: at the start of April the stock was trading far below the 30-agorot reference price, so the mechanism remained economically relevant.
Leases Are a Real Cash Use, Not Accounting Noise
It would be easy to dismiss this as an IFRS 16 footnote. That would be the wrong reading. At BioView, leases are a real cash use. In 2025 the company paid NIS 1.805 million in lease principal and another NIS 101 thousand in lease-related interest. Together that is NIS 1.906 million of cash outflow that has to be counted when asking how much flexibility is really left.
Year-end lease liabilities stood at NIS 2.793 million, of which NIS 1.298 million was current and NIS 1.495 million was long term. That is not small relative to NIS 4.92 million of cash. More importantly, lease liabilities added during 2025 totaled NIS 2.495 million, including NIS 2.142 million in buildings and NIS 353 thousand in vehicles.
The office story captures the nuance well. In October 2025 the company amended its office lease, reducing net office space by 476 square meters from March 1, 2026, while extending the remaining leased area through May 31, 2029, with an option to shorten to May 31, 2028. So there is a real efficiency move here, but not an exit from the obligation. The company reduced space; it did not eliminate the lease layer.
That is exactly why the all-in cash view is the right one. Anyone focusing only on operating cash flow misses a nearly NIS 1.9 million annual cash use that already went through the bank account. And anyone focusing only on cash misses that current lease liabilities of NIS 1.298 million are already sitting on top of that balance.
The Credit That Actually Remains Is Bank Credit, Secured and Monthly
At the start of 2026 it was possible to think BioView had a relatively clean USD 1 million bridge on the way through Inspira. The January 2026 private placement filing shows that this was never clean money. The convertible loan carried 10% annual interest, or 18% in an immediate-repayment event, and it could be converted into BioView shares at 30 agorot per share, or lower if TASE rules required that. The share issuance was capped at 27,783,367 shares, or no more than 19.99% of the pre-allocation issued share capital.
But the more important layer was the restriction package around it. The agreement limited debts and current obligations above USD 0.5 million, new liens, buybacks, and cash dividends, and it also included immediate-repayment events and cross-default provisions. In addition, funding was conditional on TASE approval for the conversion shares, on roughly USD 5 million being invested into Inspira by a third party, and on internal corporate approvals. That was not closed liquidity. It was conditional liquidity.
The annual report cuts through that story very clearly. On March 22, 2026 the conditions precedent for the Inspira convertible expired, and the parties were no longer in discussions over the activity-merger transaction. In plain terms, the USD 1 million bridge is gone.
So what is actually left? Bank credit. The company signed a NIS 3.5 million credit line with an Israeli bank on August 19, 2025, against a pledge on its securities portfolio. After the balance sheet date, during March 2026, it drew NIS 1 million from that line in the form of an On-Call loan that renews monthly and carries 7.3% annual interest.
| Funding layer | Amount | Key terms | What it means |
|---|---|---|---|
| Inspira convertible | USD 1 million | 10% interest, 18% in default, conditions precedent, limits on debt and liens, up to 19.99% of issued share capital | Looked like a bridge, but never became cash and expired in March 2026 |
| Bank line | NIS 3.5 million | Secured by the company's securities portfolio | Real credit availability, but backed by financial assets |
| Actual draw | NIS 1 million | On-Call, renews monthly, 7.3% annual interest | Expands short-term liquidity, but does not solve the capital structure |
That gap between the two layers is the core of this continuation. Inspira was supposed to bring external money together with a strategic U.S. commercialization route. It failed. What remained after the balance sheet date was NIS 1 million of monthly renewable bank debt, interest-bearing and collateralized by the investment portfolio. That buys time. It does not create freedom.
What Flexibility Is Really Left
The final picture is not catastrophic, but it is not comfortable either. At the gross cash level, BioView ended 2025 with NIS 4.92 million and added another NIS 1 million in March 2026 through bank credit. So in purely technical terms, it had NIS 5.92 million of gross liquidity after the draw.
But this is not a clean cushion. NIS 1.298 million is already classified as current lease liabilities. Leases consumed NIS 1.906 million of actual cash in 2025. NIS 1.036 million has already been recognized as an adjustment-share liability, meaning a dilution overhang that is already embedded in the balance sheet. And the extra NIS 1 million that appeared after the balance sheet date came not from strategic capital but from a monthly renewable On-Call loan secured by the company's securities portfolio.
The company itself is not describing a fully settled picture. Management states that it has sufficient financial resources for at least 12 months from the report date, but in the same note it also says that its funding plans rely mainly on sales forecasts for systems and upgrades, forecasts that had materialized only partially in the previous 12 months. That is the real test point. The question is not whether there was cash on the reporting date, but whether the quality of that cash is good enough to reach the next proof point without another dilutive round.
So the flexibility exists, but it is narrower than the headline. It is not built only on existing cash, but also on secured bank credit. It is not dilution-free, because the adjustment-share mechanism is still alive. And it is not free of real cash claims, because the lease layer already proved in 2025 that it consumes actual liquidity. For BioView, at least at this point in the story, the issue is not whether there is still air left. The issue is what kind of air it is.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.